Nirsevimab Is Protective Against Single RSV Infections, Coinfections Among Infants And Children, Study Suggests

Infectious Disease Advisor (2/3, Basilio) reports, “Among infants and children, nirsevimab was protective against single respiratory syncytial virus (RSV) infections and coinfections, according to study findings.” The researchers said, “Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses.” The findings were published in Clinical Infectious Diseases.